As part of its inquiry into TB and global health research and development (R&D) the APPG hosted two oral evidence sessions in July 2020.
Speaking to expert witnesses in the UK and internationally, officers of the APPG asked questions about the future of TB and global health R&D, the UK's research priorities moving forward, and the impact of COVID-19 on TB and global health research more broadly.
Over the course of two conference calls, the following witnesses were interviewed:
Dr Nick Chapman, CEO of Policy Cures Research
Tabitha Ha, Advocacy Manager at STOPAIDS
Professor Bertie Squire, Professor of Clinical Tropical Medicine and Dean of Clinical Sciences & International Public Health and the Liverpool School of Tropical Medicine
Sharonann Lynch, HIV & TB Policy Advisor at Médecins sans Frontières
Hester Kuipers, Executive Director Europe of IAVI
Mike Frick, TB Project Co-Director at Treatment Action Group
Dr Ben Bleasdale, Senior Policy Adviser at the Wellcome Trust
The discussions were informed by the written evidence that had already been received from a wide variety of stakeholders. Both written and oral evidence will inform the final inquiry report, which will be launched on Parliament's return in Autumn 2020.